IVIG (Intravenous Immunoglobulin) solution

IVIG (Intravenous Immunoglobulin) solution

Form: Intravenous infusion

Strength: 5% or 10%

Reference Brands: Gammagard (Gamunex-C, Flebogamma),Privigen, Octagam, Gamunex-C(US)

Category: Immune Disorder

IVIG (Intravenous Immunoglobulin) solution, marketed as Gammagard or Privigen, is approved in the US by the FDA and in the EU via EMA for passive immunity against specific infections, such as varicella-zoster and other viral diseases. Regulatory approval requires a detailed dossier including clinical efficacy, safety, manufacturing quality, and pharmacovigilance plans. In the US, the FDA rigorously reviews clinical trial and production data, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper compliance is essential for timely approval and safe use of VIG products worldwide, supporting effective infection prevention.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Belimumab prefilled syringe

Strength: 200 mg/ten 1 mL for SQ; 10 mg/mL for IV

Form: Subcutaneous (SC) and intravenous (IV) Prefilled syringe

Reference Brands: Benlysta(US & EU)

View Details Get Enquiry
Anakinra injection

Strength: 100 mg/mL

Form: Injection(SQ)

Reference Brands: Kinerso, Kineret(US)

View Details Get Enquiry
Ustekinumab Injection

Strength: SQ:: 45 mg, 90 mg; IV: 130 mg/vial

Form: SQ and IV injection

Reference Brands: Stelara(US)

View Details Get Enquiry
Everolimus tablets

Strength: 0.75 mg, 1.25 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg

Form: Tablet

Reference Brands: Zortress, Afinitor(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.